Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis

ClinicalTrials.gov ID: NCT00682643

Public ClinicalTrials.gov record NCT00682643. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 10, 2026, 3:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Two-Year Study to Evaluate the Ocular Safety of Once-Daily, Fluticasone Furoate Nasal Spray 110mcg in Adults and Adolescents 12 Years of Age and Older With Perennial Allergic Rhinitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess long-term ocular safety of fluticasone furoate nasal spray in adult and adolescent subjects diagnosed with perennial allergic rhinitis.

Study identification

NCT ID
NCT00682643
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
550 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2008
Primary completion
Jan 31, 2011
Completion
Jan 31, 2011
Last update posted
Jan 12, 2017

2008 – 2011

United States locations

U.S. sites
56
U.S. states
23
U.S. cities
52
Facility City State ZIP Site status
GSK Investigational Site Oxford Alabama 36203
GSK Investigational Site Little Rock Arkansas 72205
GSK Investigational Site Fresno California 93720
GSK Investigational Site Huntington Beach California 92647
GSK Investigational Site Los Angeles California 90025
GSK Investigational Site Mission Viejo California 92691
GSK Investigational Site Rolling Hills Estates California 90274
GSK Investigational Site Roseville California 95678
GSK Investigational Site Sacramento California 95823
GSK Investigational Site San Diego California 92120
GSK Investigational Site San Diego California 92123
GSK Investigational Site San Jose California 95117
GSK Investigational Site Stockton California 95207
GSK Investigational Site Vista California 92083
GSK Investigational Site Walnut Creek California 94598
GSK Investigational Site Colorado Springs Colorado 80907
GSK Investigational Site Denver Colorado 80230
GSK Investigational Site Englewood Colorado 80112
GSK Investigational Site Wheat Ridge Colorado 80033
GSK Investigational Site Tallahassee Florida 32308
GSK Investigational Site Conyers Georgia 30013
GSK Investigational Site Gainesville Georgia 30501
GSK Investigational Site Lawrenceville Georgia 30045
GSK Investigational Site Stockbridge Georgia 30281
GSK Investigational Site Indianapolis Indiana 46208
GSK Investigational Site South Bend Indiana 46617
GSK Investigational Site Bethesda Maryland 20814
GSK Investigational Site North Dartmouth Massachusetts 02747
GSK Investigational Site Minneapolis Minnesota 55402
GSK Investigational Site St Louis Missouri 63141
GSK Investigational Site Bozeman Montana 59718
GSK Investigational Site Bellevue Nebraska 68123-4303
GSK Investigational Site Omaha Nebraska 68130
GSK Investigational Site Omaha Nebraska 68131
GSK Investigational Site Ocean City New Jersey 07712
GSK Investigational Site Skillman New Jersey 08558
GSK Investigational Site Asheville North Carolina 28801
GSK Investigational Site Raleigh North Carolina 27607
GSK Investigational Site Canton Ohio 44718
GSK Investigational Site Cincinnati Ohio 45231
GSK Investigational Site Sylvania Ohio 43560
GSK Investigational Site Oklahoma City Oklahoma 73104
GSK Investigational Site Oklahoma City Oklahoma 73120
GSK Investigational Site Eugene Oregon 97401
GSK Investigational Site Portland Oregon 97213
GSK Investigational Site Summerville South Carolina 29485
GSK Investigational Site Austin Texas 78750
GSK Investigational Site Dallas Texas 75230
GSK Investigational Site Dallas Texas 75231-4307
GSK Investigational Site El Paso Texas 79903
GSK Investigational Site Kerrville Texas 78028
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site Waco Texas 76712
GSK Investigational Site South Burlington Vermont 05403
GSK Investigational Site Spokane Washington 99204
GSK Investigational Site Greenfield Wisconsin 53228

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00682643, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 12, 2017 · Synced Sep 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00682643 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →